Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

UCLA

Neither a doctor nor a teaching hospital

Research payments

$3,845,113

214 payments

Through program year 2025, UCLA is reported as receiving $3,845,113 in research payments, across 214 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $73,583 36
2024 Research $856,688 17
2023 Research $67,544 18
2022 Research $8,461 10
2021 Research $592,122 7
2020 Research $1,144,504 37
2019 Research $1,102,211 89

Breakdown

Who paid Research payments · program years 2019–2025
  1. Merck Sharp & Dohme Corporation $2,962,642 114 payments
  2. Celgene Corporation $199,851 4 payments
  3. Ucb SA $132,765 2 payments
  4. Novartis Pharmaceuticals Corporation $112,302 15 payments
  5. Stemline Therapeutics Inc. $111,762 2 payments
  6. Karyopharm Therapeutics Inc. $77,651 37 payments
  7. Ge Healthcare $74,561 2 payments
  8. Siemens Medical Solutions USA, Inc. $61,000 1 payment
  9. Janssen Research & Development, LLC $51,238 13 payments
  10. Verastem, Inc. $18,129 2 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase II Study of Pembrolizumab Monotherapy in Recurrent Ovarian Cancer of the Immunoreactive Subtype determined by NanoString Gene Expression Profiling. $555,178 8 payments
  2. A phase I,II trial of intratumoral administration of CCL21-gene modified dendritic cell DC combined with pembrolizumab for advanced NSCLC with low PD-L1 expression $482,346 8 payments
  3. STUDY NAME#Phase I surgical trial to evaluate early immunologic pharmacodynamic parameters for the PD-1 antibody pembrolizumab with autologous tumor lysate-pulsed dendritic cell vaccination in patients with surgically accessible recurrent,progressive glio $350,596 1 payment
  4. A Phase II Study of Pembrolizumab Monotherapy in Recurrent Ovarian Cancer of the Immunoreactive Subtype determined by NanoString Gene Expression Profiling. $325,377 1 payment
  5. STUDY NAME#A Phase II open-label, single arm pilot study to evaluate the safety and efficacy of pembrolizumab for high-grade cervical intraepithelial neoplasia $282,345 1 payment
  6. A Phase 3 Multicenter, Randomized, Double-blinded, Active-controlled, Clinical Study to Evaluate the Safety and Efficacy of Lenvatinib E7080,MK-7902 in Combination with Pembrolizumab MK-3475 Versus Lenvatinib in First-line Therapy of Participants with Advanced Hepatocellular Carcinoma LEAP-002 $191,693 16 payments
  7. A phase I,II trial of intratumoral administration of CCL21-gene modified dendritic cell DC combined with pembrolizumab for advanced NSCLC with low PD-L1 expression $172,152 1 payment
  8. A Multicenter, Randomized, Controlled, Three-Arm, Phase III Study to Evaluate the Safety and Efficacy of Two Dosing Schedules of MK-3475 Compared to Ipilimumab in Patients with Advanced Melanoma $135,196 2 payments
  9. A Phase I,II study of blinatumomab in combination with pembrolizumab MK-3475 for adults with relapsed or refractory B-lineage acute lymphoblastic leukemia with high bone marrow lymphoblast count $132,943 1 payment
  10. PhIII Ide-Cel vs Triplet RRMM 3L $122,783 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record